



# Recommendation for Cannabis Use Disorder Diagnosis in a Context of Cannabis for Therapeutic Purposes

**Clarification of the DSM-5-TR<sup>1</sup>** da fca ab e  
d .de (CUD) a d d a ca ab f.  
e a e c . e (CTP) c ca ec e f

[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]

Table. Cannabis Use Disorder (CUD) in the Context of Cannabis for Therapeutic Purposes (CTP)

Modification	DSM-5-TR criterion <sup>1</sup>
	( )
	(1) A
	(2) M
E ; 2	↘ :
▲ C D-C	▲ ( )
	(1)
	(2) C ( )
	↘ :
	( , )
	M ( , )
C D	
	I
	I : , ,
	( , )
	2-3 C : C D-C ( 2,
	▲ )
	4-5 C : C D-C
	6 C : C D-C

<sup>a</sup>Rec e dedc a e  
D M-5- CUD ec e  
f CTP dca ed.

e \_e e e e ce ca ab ea ed . be de efe- c e e ce.<sup>10</sup>F. e, eda cc ea ad .e -  
e ca ab e.<sup>5</sup>T e CUD-CTP de e ded a d a be a f. ca ab ed a ea e cc e .  
d da . a e a e .e ca a e, c a T e . ed CUD-CTP de . de a a f .  
c de ac b a f. e ca a ad ea e c e, f. c .e ea c a da e e CUD-CTP de . A a da c  
a da d CUDc e aa . de bec de ed f. c ede c b a ce a\_e  
A a . ed dfca D M-5, e CUD-CTP de ec e f c ede c-a ed ea e . T e CUD-CTP  
e .e e de ce . f. e ab , a d , a dc ca - de ad de e ec ca eed . eda c a d f  
d e e a e a e a c de a f be de e e - CUD ec e f CTP.

ARTICLE INFORMATION

Published Online: Marc 15, 2023.  
d :10.1001/a a c a .2023.0053

Conflict of Interest Disclosures: D C  
.e .ed .a f eNa al e D  
Ab e (.a DA054614-01A1) d . ec d c  
f e d . D B de a .e . ed .a f  
eNa al e D Ab ed . e  
c d c f e d . N ed c .e ee  
.e .ed .

REFERENCES

1. A e ca P c a .cA ca .D  
M M D .5 ed, e  
.e .A e ca P c a .cA ca ;2013.  
2. L LA, l e MA, Ja a c M, B e KM.  
C a ad e ca ab ed ca  
e e ce a a :e f a  
a a e. A B .2016;61:99-103.  
d :10.1016/ .addbe .2016.05.015

3. G a JM, Sc e RM, P e KW, e a .Effic  
f ed ca a a acad e a ,  
a, a d affec ed .de  
ad :a. a d ed c a .a. JAMA N O .  
2022;5(3):e222106. d :10.1001/a a e .e .  
2022.2106  
4. U ed Na .Re . f e l e a a  
Nac c C . B ad, 2018. Acce ed Feb a  
12, 2022. :// . cb. . /d c e /  
P b ca /A a Re . /AR2018/A a \_  
Re . /A a Re . \_2018\_E. df  
5. Sa a KA, Da .e MK, S RT, La b AM,  
G be SA. A e ca ab ed .de  
ed ca ca ab a e .C .2021;4(2):  
47-59. d :10.26828/ca ab /2021.02.004  
6. Ba A, S e e C, T R, Ha \_e ER,  
Se DP. P e a e c f ca ab d a a  
a e e .e a .  
de e de e f ca ab d :a e a c  
.e e a d e a a a . JAMA N O .2020;  
3(4):e202370-e202370. d :10.1001/  
a a e .e .2020.2370

7. Se M, C e C, M c e LK. A . e f  
ca ab ac e effec a d d a a :  
d ffe e a .e e ac e e a d a e .  
JA C M .2019;25(3):326-335.  
d :10.1089/ac .2018.0319  
8. V \_ ND, We SRB. l . a ce fa  
a da d d ef. ca ab .e ea c .A  
2020;115(7):1219-1221. d :10.1111/add.14984  
9. Le EA, H KP. C ca e f ca ab  
a d ca ab d e U ed Sa e . J N  
2020;411:116717. d :10.1016/ . .2020.116717  
10. A e ca P c a .cA ca Da c  
a d Sa ca Ma a Tea .G de b  
. a f .c a e DSM-5. A e ca  
P c a .cA ca .Acce ed Ja a 6, 2023.  
:// . c a . . /F e%20L ba /  
P c a . /P ac ce /DSM5-P. a -  
S b -Ge ea -G da ce. df